Next-Gen Gene Therapy Firm Kate Therapeutics Starts Out With Big Pharma Partner

Announces $51m Series A, License Deal With Astellas

 
• By Joseph Haas and Lisa Takagi
  
Adenovirus
Kate Therapeutics focuses on novel AAV vectors with smaller payloads • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Start-Ups & SMEs

More from Business